News Sentiment

KMDA sentiment intelligence

Kamada news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 56 Balanced news tone 56 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Drug Manufacturers - Specialty & Generic Read-through group
Latest close 7.12 Week of 10 Jul 2026
Weighted tone 56/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Earnings

76/100 classification confidence.

Company focus 56

directly relevant articles

Source quality 6

high-authority source matches

Trend context Trend inactive

-5.1% over one week, -4.3% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Positive

Kamada highlights study results on CYTOGAM in transplants

Market Reaction

Price moving ahead of tone

64/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Earnings 76/100 classification
One-week reaction -5.1% Price reacting lower
Trend fit Trend inactive -4.3% over four weeks
Fair value 14.9% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 21
Neutral 27
Negative 8

Relevance

Why the article matched

Direct first
Direct company coverage 56
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 7
AD HOC NEWS 5
TradingKey 5
Investing.com 3
DonanımHaber 3
GuruFocus 2
GlobeNewswire 2
TradingView 2

Event Lens

What the news is about

Classified themes
Earnings 24
Market update 23
Regulatory and legal 6
Analyst action 2
Capital return 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 56
Investing.com Direct company coverage

Kamada highlights study results on CYTOGAM in transplants

Kamada Ltd. presented positive study results for its CYTOGAM product at a recent International Society for Heart and Lung Transplant meeting, showing improved outcomes for high-risk lung transplant recipients. The company, which reported strong Q1 2026 revenues and reaffirmed its

Tone
Positive 73/100
Event
Earnings
Published
14 Jul 2026 07:10
Source
Investing.com
Investing.com Nigeria Direct company coverage

Kamada highlights study results on CYTOGAM in transplants By Investing.com

Kamada Ltd. announced positive results from an investigator-initiated study on its CYTOGAM product for solid organ transplantation, presented at the 2026 International Society for Heart and Lung Transplant annual meeting. The study indicated that high-risk lung transplant recipie

Tone
Positive 75/100
Event
Earnings
Published
13 Jul 2026 12:40
Source
Investing.com Nigeria
Stock Titan Direct company coverage

[6-K] KAMADA LTD Current Report (Foreign Issuer) | KMDA SEC Filing - Form 6-K

Kamada Ltd. (NASDAQ: KMDA) has filed a Form 6-K report highlighting new results from an Investigator-Initiated Study on its Cytomegalovirus Immune Globulin (CMVIG), CYTOGAM®, presented at the 2026 ISHLT annual meeting. The study indicates that CMVIG prophylaxis is associated with

Tone
Positive 74/100
Event
Earnings
Published
13 Jul 2026 12:12
Source
Stock Titan
Stock Titan Direct company coverage

Immune drug CYTOGAM tied to better outcomes in high‑risk lung transplant patients

Kamada (NASDAQ: KMDA) announced new data from an Investigator-Initiated Study demonstrating that its immune globulin product, CYTOGAM, is associated with improved outcomes in high-risk lung transplant recipients. Presented at the 2026 ISHLT annual meeting, the findings, which com

Tone
Positive 72/100
Event
Market update
Published
13 Jul 2026 11:12
Source
Stock Titan
Stock Traders Daily Direct company coverage

How (KMDA) Movements Inform Risk Allocation Models

This article analyzes Kamada Ltd. (NASDAQ: KMDA) using AI models, identifying weak near-term sentiment but strong long-term potential. It provides three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored to different risk profiles. The anal

Tone
Negative 38/100
Event
Market update
Published
12 Jul 2026 06:45
Source
Stock Traders Daily
AD HOC NEWS Direct company coverage

Kamada Ltd outlines plasma-derived therapies strategy. Investor focus on specialty biologics pipeline grows

Kamada Ltd (KMDA) is a specialty biopharmaceutical company focused on plasma-derived and other biologic therapies for rare and serious conditions, listed on Nasdaq. The company's strategy involves controlling plasma fractionation, focusing on rare disease markets with in-house de

Tone
Positive 74/100
Event
Market update
Published
07 Jul 2026 21:30
Source
AD HOC NEWS
AD HOC NEWS Direct company coverage

Kamada Ltd updates drug portfolio as Nasdaq-listed biopharma pursues growth

Kamada Ltd, a Nasdaq-listed biopharma company, is refining its drug portfolio, focusing on specialty plasma-derived and hyperimmune globulin products for rare and underserved indications. The company, headquartered in Israel, offers US investors exposure to its niche through Amer

Tone
Positive 66/100
Event
Market update
Published
30 Jun 2026 12:40
Source
AD HOC NEWS
Quartr Direct company coverage

Kamada (KMDA) Corporate Presentation Summary

This article summarizes a corporate presentation by Kamada (KMDA) from December 12, 2025, highlighting its strong financial performance with 2025 revenue guidance of $178–182M and significant year-over-year growth in revenue, gross profit, and adjusted EBITDA. The company boasts

Tone
Positive 70/100
Event
Earnings
Published
27 Jun 2026 17:39
Source
Quartr
Intellectia AI Direct company coverage

KMDA Financials: Revenue Breakdown, Margins & Competitor Comparison

The article analyzes Kamada Ltd's (KMDA) financial performance, highlighting its revenue breakdown, profitability margins, and competitive standing. Proprietary Products contribute the majority (85.9%) of its revenue. KMDA's margins, including a gross margin of 42.25% and a net m

Tone
Positive 65/100
Event
Earnings
Published
23 Jun 2026 23:41
Source
Intellectia AI
AD HOC NEWS Direct company coverage

Kamada Stock - weekly review against biotech peers

This article provides a weekly review of Kamada stock (KMDA), noting its quiet trading in the mid-single digits without fresh company news. The focus is on how Kamada, an Israeli plasma-derived protein specialist, compares to its mid-cap biotech peers and its recent fundamentals.

Tone
Neutral 50/100
Event
Market update
Published
19 Jun 2026 20:18
Source
AD HOC NEWS
TradingKey Direct company coverage

Kamada Ltd (KMDA) Earnings Forecast: Future EPS & Revenue Growth Estimates

Kamada Ltd (KMDA) has an earnings forecast score of 8.67, ranking 13th in the Pharmaceuticals industry. Analysts have an average price target of $13.00 for KMDA, with a "Buy" trend recommendation from three analysts. The company's expected revenue for the next quarter is $50.66M,

Tone
Positive 74/100
Event
Earnings
Published
18 Jun 2026 21:11
Source
TradingKey
Investing.com Direct company coverage

Kamada schedules annual shareholder meeting for August in Rehovot

Kamada Ltd. (NASDAQ:KMDA) has announced that its Annual General Meeting of Shareholders will be held on Wednesday, August 5, 2026, at 4:00 p.m. Israel time. The meeting will take place at the company's offices in Rehovot, Israel. A notice and proxy statement have been prepared an

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 11:39
Source
Investing.com
Stock Titan Direct company coverage

Kamada (NASDAQ: KMDA) plans 2026 AGM on directors, option grants and ISO pool

Kamada Ltd. will hold its Annual General Meeting of Shareholders on August 5, 2026, to vote on the re-election of directors, approve equity option grants for nominees, and amend the U.S. Taxpayers Appendix of its 2011 Israeli Share Award Plan to increase the incentive stock optio

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 10:39
Source
Stock Titan
TradingKey Direct company coverage

Kamada Ltd (KMDA) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Kamada Ltd (KMDA), noting its current valuation score of 8.07, which ranks it 113 out of 157 in the Pharmaceuticals industry. It highlights the company's P/E ratio of 20.72, showing a significant deviation from its recent high and low

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 07:39
Source
TradingKey
TradingKey Direct company coverage

Kamada Ltd (KMDA) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Kamada Ltd (KMDA), detailing its current price momentum score of 6.81, ranking 96 out of 157 in the Pharmaceuticals industry. It highlights the stock trading between resistance at $7.84 and support at $6.88, suggesting suitability for

Tone
Negative 29/100
Event
Market update
Published
18 Jun 2026 07:39
Source
TradingKey
TradingKey Direct company coverage

Kamada Ltd (KMDA) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Kamada Ltd (KMDA), detailing its current risk score of 4.17 and ranking it 91 out of 157 in the Pharmaceuticals industry. Key metrics like beta (0.87), maximum drawdown, volatility, and Sharpe ratios are presented to illustrate the stoc

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 07:11
Source
TradingKey
TradingKey Direct company coverage

Kamada Ltd (KMDA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Kamada Ltd (KMDA), detailing its revenue by region. The data shows the United States accounts for the majority of revenue at 55.22%, followed by Israel, Latin America, Canada, and Europe. The report also notes that specific data for b

Tone
Neutral 50/100
Event
Earnings
Published
18 Jun 2026 03:11
Source
TradingKey
AD HOC NEWS Direct company coverage

Kamada Ltd stock (IL0010952647): Biopharma player focuses on plasma and inhaled therapies after rece

Kamada Ltd, an Israeli biopharmaceutical company, specializing in plasma-derived products and inhaled therapies, has experienced recent stock weakness despite its strategic focus. The company develops and markets treatments for rare and serious conditions, including alpha-1 antit

Tone
Neutral 50/100
Event
Market update
Published
11 Jun 2026 05:40
Source
AD HOC NEWS
AD HOC NEWS Direct company coverage

Kamada Ltd stock (IL0010952647): Biopharma player focuses on plasma and inhaled therapies after recent share weakness

Kamada Ltd, an Israeli biopharma company, continues to focus on specialty plasma-derived products and inhaled therapies despite recent stock weakness. The company develops, manufactures, and markets products for rare and serious conditions, including AAT deficiency and immune def

Tone
Neutral 50/100
Event
Market update
Published
10 Jun 2026 15:10
Source
AD HOC NEWS
Market source Direct company coverage

Kamada Announces FDA Approval of its New In-House Rabies Virus Neutralization Testing Laboratory

Kamada Ltd. announced FDA approval for its new in-house Rapid Fluorescent Focus Inhibition Test (RFFIT) laboratory. This state-of-the-art facility, also approved by Health Canada and the Israeli Ministry of Health, will enhance Kamada's capabilities for Anti-Rabies potency testin

Tone
Positive 75/100
Event
Regulatory and legal
Published
03 Jun 2026 20:10
Source
Market source
Investing.com Direct company coverage

Kamada receives FDA approval for rabies antibody testing lab

Kamada Ltd. announced that the U.S. FDA has approved its new in-house Rapid Fluorescent Focus Inhibition Test (RFFIT) laboratory in Israel for potency testing of its anti-rabies products, KEDRAB and KAMRAB. This approval follows prior authorizations from Health Canada and the Isr

Tone
Positive 72/100
Event
Regulatory and legal
Published
02 Jun 2026 02:39
Source
Investing.com
Investing.com Canada Direct company coverage

Kamada receives FDA approval for rabies antibody testing lab By Investing.com

Kamada Ltd. announced FDA approval for its new Rapid Fluorescent Focus Inhibition Test (RFFIT) laboratory in Israel. This lab will conduct potency testing for their anti-rabies products, KEDRAB and KAMRAB, which generated over $70 million in sales in 2025. The approval is expecte

Tone
Positive 73/100
Event
Regulatory and legal
Published
01 Jun 2026 11:40
Source
Investing.com Canada
Stock Titan Direct company coverage

Kamada (KMDA) wins FDA approval for in-house RFFIT rabies antibody testing lab

Kamada Ltd. (NASDAQ: KMDA) announced that the FDA has approved its new in-house Rapid Fluorescent Focus Inhibition Test (RFFIT) laboratory. This lab, located in Israel and previously approved by Health Canada and the Israeli Ministry of Health, will be used for Anti-Rabies potenc

Tone
Positive 73/100
Event
Regulatory and legal
Published
01 Jun 2026 10:40
Source
Stock Titan
Stock Titan Direct company coverage

Rabies antibody testing: FDA approves Kamada’s rare gold-standard lab

Kamada (NASDAQ: KMDA) has received FDA approval for its new in-house Rapid Fluorescent Focus Inhibition Test (RFFIT) rabies virus neutralization laboratory located in Beit Kama, Israel. This lab significantly expands the company's testing capabilities for its anti-rabies products

Tone
Positive 73/100
Event
Regulatory and legal
Published
01 Jun 2026 10:40
Source
Stock Titan
Finviz Direct company coverage

KMDA - Kamada Ltd Stock Price and Quote

This article provides comprehensive financial data and news for Kamada Ltd (KMDA), a biopharmaceutical company specializing in plasma-derived therapeutics. It includes real-time stock quotes, key financial metrics, insider ownership, analyst ratings, and a chronological list of r

Tone
Positive 67/100
Event
Analyst action
Published
01 Jun 2026 02:08
Source
Finviz